Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03609671 · ClinicalTrials.gov registry record · NA

Emotions Immunology and Breast Cancer

A NA study of Breast Cancer and Triple Negative Breast Cancer, sponsored by Luz A. Venta, MD.

Completed
Registry status
NA
Development phase
17
Enrollment target
2
Study locations

NCT03609671 is a NA study of Breast Cancer and Triple Negative Breast Cancer that has completed, run by Luz A. Venta, MD. The registered enrollment target is 17 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03609671, a NA study of Breast Cancer and Triple Negative Breast Cancer, has completed, sponsored by Luz A. Venta, MD.

COMPLETED
Registry status
NA
Development phase
17 participants
Enrollment target
2
Study locations

Study Summary

Pilot study representing a proof of concept regarding the potential for immune system enhancement with psychotherapy, resulting in improved immunological response at lumpectomy or mastectomy in patients undergoing neoadjuvant chemotherapy.

Interventions

  • BEHAVIORAL Standard of Care + Experimental Individualized Therapy
  • OTHER Control: Standard of Care

Study Locations (2)

Texas

  • Houston Methodist Hospital Cancer Center - Houston
  • Houston Methodist Hospital - Houston

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2015-11-23
Est. Completion 2019-03-18
Phase NA

Sponsor

Luz A. Venta, MD

1 total trials

What the Registry Record Tells You About NCT03609671

The ClinicalTrials.gov registry entry for NCT03609671 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Luz A. Venta, MD, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care + Experimental Individualized Therapy is the first listed.

NCT03609671 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT03609671 about?

NCT03609671 is a clinical study titled "Emotions Immunology and Breast Cancer". Pilot study representing a proof of concept regarding the potential for immune system enhancement with psychotherapy, resulting in improved immunological response at lumpectomy or mastectomy in patients undergoing neoadjuvant chemotherapy.

What is the current status of trial NCT03609671?

This trial is currently completed. It is a NA study. The enrollment target is 17 participants. The study started on 2015-11-23. Estimated completion is 2019-03-18.

What conditions does trial NCT03609671 study?

This clinical trial studies the following conditions: Breast Cancer, Triple Negative Breast Cancer, Emotions, Immunology.

What interventions are being tested in trial NCT03609671?

The interventions under investigation include: Standard of Care + Experimental Individualized Therapy (BEHAVIORAL), Control: Standard of Care (OTHER).

Who is sponsoring clinical trial NCT03609671?

This trial is sponsored by Luz A. Venta, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03609671 being conducted?

This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.